# Gencor Industries Inc: financial statements, quarterly

GENC · NYSE · CIK 64472 · [Industrials](/sectors/industrials.md) · fiscal year ends Sep 30

Pages: [Overview](/companies/genc.md) · [Financials](/companies/genc/financials.md) · [Filings](/companies/genc/filings.md) · [Insiders](/companies/genc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/genc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [20.9 d](/filings/0001193125-25-150836.md) | [26.0](/filings/0001193125-25-164836.md) | [40.7](/filings/0001193125-25-164840.md) | [25.6](/filings/0001193125-25-176039.md) | [20.9 d](/filings/0001193125-25-312742.md) | [31.4](/filings/0001193125-26-040319.md) | [38.2](/filings/0001193125-26-269656.md) | [27.0](/filings/0001193125-26-341429.md) | [18.8 d](/filings/0001193125-25-312742.md) | [23.6](/filings/0001193125-26-040319.md) | [33.8](/filings/0001193125-26-269656.md) | [33.8](/filings/0001193125-26-341429.md) |
| Cost of revenue | $m | [14.3 d](/filings/0001193125-25-150836.md) | [18.5](/filings/0001193125-25-164836.md) | [28.4](/filings/0001193125-25-164840.md) | [19.4](/filings/0001193125-25-176039.md) | [15.6 d](/filings/0001193125-25-312742.md) | [22.7](/filings/0001193125-26-040319.md) | [26.9](/filings/0001193125-26-269656.md) | [19.8](/filings/0001193125-26-341429.md) | [14.3 d](/filings/0001193125-25-312742.md) | [16.8](/filings/0001193125-26-040319.md) | [23.1](/filings/0001193125-26-269656.md) | [24.4](/filings/0001193125-26-341429.md) |
| Gross profit | $m | [6.6 d](/filings/0001193125-25-150836.md) | [7.5](/filings/0001193125-25-164836.md) | [12.3](/filings/0001193125-25-164840.md) | [6.1](/filings/0001193125-25-176039.md) | [5.4 d](/filings/0001193125-25-312742.md) | [8.7](/filings/0001193125-26-040319.md) | [11.4](/filings/0001193125-26-269656.md) | [7.1](/filings/0001193125-26-341429.md) | [4.5 d](/filings/0001193125-25-312742.md) | [6.8](/filings/0001193125-26-040319.md) | [10.7](/filings/0001193125-26-269656.md) | [9.4](/filings/0001193125-26-341429.md) |
| Research and development | $m | [0.8 d](/filings/0001193125-25-150836.md) | [0.8](/filings/0001193125-25-164836.md) | [0.9](/filings/0001193125-25-164840.md) | [0.8](/filings/0001193125-25-176039.md) | [0.8 d](/filings/0001193125-25-312742.md) | [0.7](/filings/0001193125-26-040319.md) | [0.7](/filings/0001193125-26-269656.md) | [0.7](/filings/0001193125-26-341429.md) | [0.7 d](/filings/0001193125-25-312742.md) | [0.8](/filings/0001193125-26-040319.md) | [0.6](/filings/0001193125-26-269656.md) | [0.7](/filings/0001193125-26-341429.md) |
| Selling, general and administrative | $m | [3.1 d](/filings/0001193125-25-150836.md) | [3.4](/filings/0001193125-25-164836.md) | [4.4](/filings/0001193125-25-164840.md) | [3.3](/filings/0001193125-25-176039.md) | [3.3 d](/filings/0001193125-25-312742.md) | [3.4](/filings/0001193125-26-040319.md) | [4.2](/filings/0001193125-26-269656.md) | [3.3](/filings/0001193125-26-341429.md) | [4.1 d](/filings/0001193125-25-312742.md) | [2.9](/filings/0001193125-26-040319.md) | [5.8](/filings/0001193125-26-269656.md) | [3.0](/filings/0001193125-26-341429.md) |
| Operating income | $m | [2.7 d](/filings/0001193125-25-150836.md) | [3.4](/filings/0001193125-25-164836.md) | [7.1](/filings/0001193125-25-164840.md) | [2.0](/filings/0001193125-25-176039.md) | [1.2 d](/filings/0001193125-25-312742.md) | [4.6](/filings/0001193125-26-040319.md) | [6.5](/filings/0001193125-26-269656.md) | [3.1](/filings/0001193125-26-341429.md) | [(0.2) d](/filings/0001193125-25-312742.md) | [3.1](/filings/0001193125-26-040319.md) | [4.2](/filings/0001193125-26-269656.md) | [5.8](/filings/0001193125-26-341429.md) |
| Income tax | $m | [0.5 d](/filings/0001193125-25-150836.md) | [1.3](/filings/0001193125-25-164836.md) | [1.9](/filings/0001193125-25-164840.md) | [0.8](/filings/0001193125-25-176039.md) | [2.3 d](/filings/0001193125-25-312742.md) | [1.3](/filings/0001193125-26-040319.md) | [2.1](/filings/0001193125-26-269656.md) | [1.3](/filings/0001193125-26-341429.md) | [(0.3) d](/filings/0001193125-25-312742.md) | [1.2](/filings/0001193125-26-040319.md) | [1.3](/filings/0001193125-26-269656.md) | [1.5](/filings/0001193125-26-341429.md) |
| Net income | $m | [3.1 d](/filings/0001193125-25-150836.md) | [4.3](/filings/0001193125-25-176039.md) | [6.2](/filings/0001193125-25-176039.md) | [2.6](/filings/0001193125-25-176039.md) | [1.5 d](/filings/0001193125-25-312742.md) | [3.8](/filings/0001193125-26-341429.md) | [6.1](/filings/0001193125-26-341429.md) | [3.8](/filings/0001193125-26-341429.md) | [1.9 d](/filings/0001193125-25-312742.md) | [3.4](/filings/0001193125-26-341429.md) | [3.8](/filings/0001193125-26-341429.md) | [5.7](/filings/0001193125-26-341429.md) |
| Diluted EPS | $ per share | not reported | [0.30](/filings/0001193125-25-164836.md) | [0.42](/filings/0001193125-25-164840.md) | [0.17](/filings/0001193125-25-176039.md) | not reported | [0.26](/filings/0001193125-26-040319.md) | [0.42](/filings/0001193125-26-269656.md) | [0.26](/filings/0001193125-26-341429.md) | not reported | [0.23](/filings/0001193125-26-040319.md) | [0.26](/filings/0001193125-26-269656.md) | [0.39](/filings/0001193125-26-341429.md) |
| Basic EPS | $ per share | not reported | [0.30](/filings/0001193125-25-164836.md) | [0.42](/filings/0001193125-25-164840.md) | [0.17](/filings/0001193125-25-176039.md) | not reported | [0.26](/filings/0001193125-26-040319.md) | [0.42](/filings/0001193125-26-269656.md) | [0.26](/filings/0001193125-26-341429.md) | not reported | [0.23](/filings/0001193125-26-040319.md) | [0.26](/filings/0001193125-26-269656.md) | [0.39](/filings/0001193125-26-341429.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [17.0](/filings/0001193125-25-150836.md) | [18.6](/filings/0001193125-24-025282.md) | [30.2](/filings/0001193125-24-135800.md) | [28.8](/filings/0001193125-24-197832.md) | [25.5](/filings/0001193125-25-312742.md) | [40.0](/filings/0001193125-25-164836.md) | [52.3](/filings/0001193125-25-164840.md) | [27.9](/filings/0001193125-25-176039.md) | [26.6](/filings/0001193125-26-341429.md) | [36.7](/filings/0001193125-26-040319.md) | [43.5](/filings/0001193125-26-269656.md) | [26.3](/filings/0001193125-26-341429.md) |
| Current assets | $m | [179](/filings/0001193125-25-150836.md) | [190](/filings/0001193125-24-025282.md) | [190](/filings/0001193125-24-135800.md) | [186](/filings/0001193125-24-197832.md) | [193](/filings/0001193125-25-312742.md) | [203](/filings/0001193125-25-164836.md) | [209](/filings/0001193125-25-164840.md) | [205](/filings/0001193125-25-176039.md) | [207](/filings/0001193125-26-341429.md) | [212](/filings/0001193125-26-040319.md) | [221](/filings/0001193125-26-269656.md) | [223](/filings/0001193125-26-341429.md) |
| Total assets | $m | [196](/filings/0001193125-25-150836.md) | [206](/filings/0001193125-24-025282.md) | [206](/filings/0001193125-24-135800.md) | [202](/filings/0001193125-24-197832.md) | [208](/filings/0001193125-25-312742.md) | [218](/filings/0001193125-25-164836.md) | [224](/filings/0001193125-25-164840.md) | [220](/filings/0001193125-25-176039.md) | [223](/filings/0001193125-26-341429.md) | [229](/filings/0001193125-26-040319.md) | [237](/filings/0001193125-26-269656.md) | [239](/filings/0001193125-26-341429.md) |
| Current liabilities | $m | [14.2](/filings/0001193125-25-150836.md) | [19.7](/filings/0001193125-24-025282.md) | [13.8](/filings/0001193125-24-135800.md) | [7.0](/filings/0001193125-24-197832.md) | [10.6](/filings/0001193125-25-312742.md) | [16.7](/filings/0001193125-25-164836.md) | [15.9](/filings/0001193125-25-164840.md) | [8.3](/filings/0001193125-25-176039.md) | [8.8](/filings/0001193125-26-341429.md) | [11.5](/filings/0001193125-26-040319.md) | [15.6](/filings/0001193125-26-269656.md) | [11.6](/filings/0001193125-26-341429.md) |
| Total liabilities | $m | [14.3](/filings/0001193125-25-150836.md) | [19.7](/filings/0001193125-24-025282.md) | [13.9](/filings/0001193125-24-135800.md) | [7.1](/filings/0001193125-24-197832.md) | [12.0](/filings/0001193125-25-312742.md) | [18.2](/filings/0001193125-25-164836.md) | [17.9](/filings/0001193125-25-164840.md) | [10.3](/filings/0001193125-25-176039.md) | [10.8](/filings/0001193125-26-341429.md) | [13.7](/filings/0001193125-26-040319.md) | [18.0](/filings/0001193125-26-269656.md) | [14.2](/filings/0001193125-26-341429.md) |
| Long-term debt | $m | [0.0](/filings/0001193125-25-150836.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-25-312742.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-25-312742.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [182](/filings/0001193125-25-312742.md) | [186](/filings/0001193125-25-176039.md) | [192](/filings/0001193125-25-176039.md) | [195](/filings/0001193125-25-176039.md) | [196](/filings/0001193125-26-341429.md) | [200](/filings/0001193125-26-341429.md) | [206](/filings/0001193125-26-341429.md) | [210](/filings/0001193125-26-341429.md) | [212](/filings/0001193125-26-341429.md) | [215](/filings/0001193125-26-341429.md) | [219](/filings/0001193125-26-341429.md) | [225](/filings/0001193125-26-341429.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-09-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [11.8 d](/filings/0001193125-25-150836.md) | [1.9](/filings/0001193125-25-164836.md) | [11.7 d](/filings/0001193125-25-164840.md) | [(1.0) d](/filings/0001193125-25-176039.md) | [(3.2) d](/filings/0001193125-25-312742.md) | [14.8](/filings/0001193125-26-040319.md) | [12.4 d](/filings/0001193125-26-269656.md) | [(23.9) d](/filings/0001193125-26-341429.md) | [(0.3) d](/filings/0001193125-25-312742.md) | [11.1](/filings/0001193125-26-040319.md) | [6.9 d](/filings/0001193125-26-269656.md) | [(16.7) d](/filings/0001193125-26-341429.md) |
| Capital expenditure | $m | [1.0 d](/filings/0001193125-25-150836.md) | [0.4](/filings/0001193125-25-164836.md) | [0.0 d](/filings/0001193125-25-164840.md) | [0.4 d](/filings/0001193125-25-176039.md) | [0.1 d](/filings/0001193125-25-312742.md) | [0.3](/filings/0001193125-26-040319.md) | [0.1 d](/filings/0001193125-26-269656.md) | [0.5 d](/filings/0001193125-26-341429.md) | [1.0 d](/filings/0001193125-25-312742.md) | [1.0](/filings/0001193125-26-040319.md) | [0.2 d](/filings/0001193125-26-269656.md) | [0.5 d](/filings/0001193125-26-341429.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q1 FY2023 (2022-12-31) | Q2 FY2023 (2023-03-31) | Q3 FY2023 (2023-06-30) | Q1 FY2024 (2023-12-31) | Q2 FY2024 (2024-03-31) | Q3 FY2024 (2024-06-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.7](/filings/0001193125-24-025282.md) | [14.7](/filings/0001193125-24-135800.md) | [14.7](/filings/0001193125-24-197832.md) | [14.7](/filings/0001193125-25-164836.md) | [14.7](/filings/0001193125-25-164840.md) | [14.7](/filings/0001193125-25-176039.md) | [14.7](/filings/0001193125-26-040319.md) | [14.7](/filings/0001193125-26-269656.md) | [14.7](/filings/0001193125-26-341429.md) | [14.7](/filings/0001193125-26-040319.md) | [14.7](/filings/0001193125-26-269656.md) | [14.7](/filings/0001193125-26-341429.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 8,008,632 at 2014-08-04, from the cover of the [10-Q filed 2014-08-05](/filings/0001193125-14-295545.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.